Literature DB >> 19778944

The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis.

Lorna R Fiedler1, Tiziana Bachetti, James Leiper, Ian Zachary, Lihua Chen, Thomas Renné, Beata Wojciak-Stothard.   

Abstract

OBJECTIVE: Asymmetrical dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor and cardiovascular risk factor associated with angiogenic disorders. Enzymes metabolising ADMA, dimethylarginine dimethylaminohydrolases (DDAH) promote angiogenesis, but the mechanisms are not clear. We hypothesized that ADMA/DDAH modifies endothelial responses to vascular endothelial growth factor (VEGF) by affecting activity of Rho GTPases, regulators of actin polymerization, and focal adhesion dynamics. METHODS AND
RESULTS: The effects of ADMA on VEGF-induced endothelial cell motility, focal adhesion turnover, and angiogenesis were studied in human umbilical vein endothelial cells (HUVECs) and DDAH I heterozygous knockout mice. ADMA inhibited VEGF-induced chemotaxis in vitro and angiogenesis in vitro and in vivo in an NO-dependent way. ADMA effects were prevented by overexpression of DDAH but were not associated with decreased proliferation, increased apoptosis, or changes in VEGFR-2 activity or expression. ADMA inhibited endothelial cell polarization, protrusion formation, and decreased focal adhesion dynamics, resulting from Rac1 inhibition after decrease in phosphorylation of vasodilator stimulated phosphoprotein (VASP). Constitutively active Rac1, and to a lesser extent dominant negative RhoA, abrogated ADMA effects in vitro and in vivo.
CONCLUSIONS: The ADMA/DDAH pathway regulates VEGF-induced angiogenesis in an NO- and Rac1-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19778944     DOI: 10.1161/ATVBAHA.109.194035

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  Single-lineage transcriptome analysis reveals key regulatory pathways in primitive erythroid progenitors in the mouse embryo.

Authors:  Joan Isern; Zhiyong He; Stuart T Fraser; Sonja Nowotschin; Anna Ferrer-Vaquer; Rebecca Moore; Anna-Katerina Hadjantonakis; Vincent Schulz; David Tuck; Patrick G Gallagher; Margaret H Baron
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

Review 2.  Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?

Authors:  Ben Caplin; James Leiper
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-29       Impact factor: 8.311

3.  Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function.

Authors:  Hilda Tsang; James Leiper; Ka Hou Lao; Laura Dowsett; Matthew W Delahaye; Gareth Barnes; John Wharton; Luke Howard; Lucio Iannone; Ninian N Lang; Martin R Wilkins; Beata Wojciak-Stothard
Journal:  Pulm Circ       Date:  2013-12-04       Impact factor: 3.017

4.  Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension.

Authors:  Beata Wojciak-Stothard; Vahitha B Abdul-Salam; Ka Hou Lao; Hilda Tsang; David C Irwin; Christina Lisk; Zoe Loomis; Kurt R Stenmark; John C Edwards; Stuart H Yuspa; Luke S Howard; Robert J Edwards; Christopher J Rhodes; J Simon R Gibbs; John Wharton; Lan Zhao; Martin R Wilkins
Journal:  Circulation       Date:  2014-02-06       Impact factor: 29.690

5.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

6.  An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma.

Authors:  Melanie Gschaider; Friederike Neumann; Bettina Peters; Florian Lenz; Michael Cibena; Malgorzata Goiser; Ingrid Wolf; Jörg Wenzel; Cornelia Mauch; Wolfgang Schreiner; Stephan N Wagner
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

7.  Visfatin/PBEF/Nampt: A New Cardiovascular Target?

Authors:  Concepción Peiró; Tania Romacho; Raffaele Carraro; Carlos F Sánchez-Ferrer
Journal:  Front Pharmacol       Date:  2010-11-23       Impact factor: 5.810

8.  Nitric oxide manipulation: a therapeutic target for peripheral arterial disease?

Authors:  Gareth Williams; Xu Shi-Wen; David Abraham; Sadasivam Selvakumar; Daryll M Baker; Janice C S Tsui
Journal:  Cardiol Res Pract       Date:  2012-03-20       Impact factor: 1.866

9.  Evaluation of Blood Coagulation Parameters and ADMA, NO, IL-6, and IL-18 Serum Levels in Patients with Neovascular AMD before, during, and after the Initial Loading Phase of Intravitreal Aflibercept.

Authors:  Michał Wiciński; Małgorzata Seredyka-Burduk; Sławomir Liberski; Daria Marczak; Magdalena Pol; Bartosz Malinowski; Katarzyna Pawlak-Osińska; Bartlomiej J Kaluzny
Journal:  Life (Basel)       Date:  2021-05-14

10.  Plasmodium Infection Is Associated with Impaired Hepatic Dimethylarginine Dimethylaminohydrolase Activity and Disruption of Nitric Oxide Synthase Inhibitor/Substrate Homeostasis.

Authors:  Jessica H Chertow; Matthew S Alkaitis; Glenn Nardone; Allison K Ikeda; Aubrey J Cunnington; Joseph Okebe; Augustine O Ebonyi; Madi Njie; Simon Correa; Shamanthi Jayasooriya; Climent Casals-Pascual; Oliver Billker; David J Conway; Michael Walther; Hans Ackerman
Journal:  PLoS Pathog       Date:  2015-09-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.